Որոնման արդյունքները - Charles D. Blanke
- Ցուցադրվում են 1 - 20 արդյունքները 67
- Գնացեք Հաջորդ էջ
-
1
-
2
-
3
-
4
-
5
-
6
Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415) Philip J. Gold, Bryan Goldman, Syma Iqbal, Lawrence P. Leichman, Wu Zhang, Heinz‐Josef Lenz, Charles D. Blanke
Հրապարակվել է 2010Artigo -
7
Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors George D. Demetri, Yanfeng Wang, Elisabeth Wehrle, Amy Racine, Zariana Nikolova, Charles D. Blanke, Heikki Joensuu, Margaret von Mehren
Հրապարակվել է 2009Artigo -
8
-
9
Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer Syma Iqbal, Bryan Goldman, Cecilia M. Fenoglio‐Preiser, Heinz‐Josef Lenz, W. Zhang, K. D. Danenberg, Stephen Shibata, Charles D. Blanke
Հրապարակվել է 2011Artigo -
10
Let’s Talk About Those Herbs You Are Taking: Ethical Considerations for Communication With Patients With Cancer About Complementary and Alternative Medicine Laura Tenner, Fay J. Hlubocky, Charles D. Blanke, Thomas W. LeBlanc, Jonathan M. Marron, Molly McGinnis, Rebecca Spence, Lynne P. Taylor
Հրապարակվել է 2019Artigo -
11
-
12
Cetuximab Plus Cisplatin, Irinotecan, and Thoracic Radiotherapy as Definitive Treatment for Locally Advanced, Unresectable Esophageal Cancer: A Phase-II Study of The SWOG (S0414) Michael Tomblyn, Bryan Goldman, Charles R. Thomas, Jacqueline Benedetti, Heinz‐Josef Lenz, Vivek Mehta, Thaddeus Beeker, Philip J. Gold, James L. Abbruzzese, Charles D. Blanke
Հրապարակվել է 2012Artigo -
13
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma Anthony B. El-Khoueiry, Cathryn Rankin, A.B. Siegel, Syma Iqbal, I-Y Gong, Kenneth C. Micetich, Omar Kayaleh, H-J Lenz, Charles D. Blanke
Հրապարակվել է 2014Artigo -
14
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma Anthony B. El-Khoueiry, Cathryn Rankin, Edgar Ben‐Josef, Heinz‐Josef Lenz, Philip J. Gold, Robert D. Hamilton, Rangaswamy Govindarajan, Cathy Eng, Charles D. Blanke
Հրապարակվել է 2011Artigo -
15
Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer Kathy D. Miller, Joel Picus, Charles D. Blanke, William J. John, Jeffrey W. Clark, Lawrence N. Shulman, D. Thornton, Eric K. Rowinsky, Patrick J. Loehrer
Հրապարակվել է 2000Artigo -
16
Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials Charles D. Blanke, Brian M. Bot, David M. Thomas, Archie Bleyer, Claus-Henning Köhne, Michel Seymour, Aimery de Gramont, Richard M. Goldberg, Daniel J. Sargent
Հրապարակվել է 2011Artigo -
17
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336) Robert P. Whitehead, Cathryn Rankin, Paulo M. Hoff, Philip J. Gold, Kevin G. Billingsley, Robert Chapman, Lucas Wong, John H. Ward, James L. Abbruzzese, Charles D. Blanke
Հրապարակվել է 2008Artigo -
18
End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal Carmen J. Allegra, Charles D. Blanke, Marc Buyse, Richard M. Goldberg, Axel Grothey, Neal J. Meropol, Leonard B. Saltz, Alan P. Venook, Greg Yothers, Daniel J. Sargent
Հրապարակվել է 2007Revisão -
19
Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gem... Philip A. Philip, Bryan Goldman, Ramesh K. Ramanathan, Heinz‐Josef Lenz, Andrew M. Lowy, Robert P. Whitehead, Takeru Wakatsuki, Syma Iqbal, Rakesh Gaur, Jacqueline Benedetti, Charles D. Blanke
Հրապարակվել է 2014Artigo -
20
Phase 2 study of <scp>MK</scp>‐2206, an allosteric inhibitor of <scp>AKT</scp>, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative... Ramesh K. Ramanathan, Shannon McDonough, Hagen F. Kennecke, Syma Iqbal, Joaquina Baranda, Tara Elisabeth Seery, Howard J. Lim, Aram F. Hezel, Gina M. Vaccaro, Charles D. Blanke
Հրապարակվել է 2015Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Medicine
Internal medicine
Cancer
Oncology
Gastroenterology
Chemotherapy
Colorectal cancer
Clinical trial
Surgery
Clinical endpoint
Phases of clinical research
Confidence interval
Biology
Hazard ratio
Imatinib
Myeloid leukemia
Stromal cell
GiST
Oxaliplatin
Adverse effect
Cetuximab
Imatinib mesylate
Randomized controlled trial
Adjuvant therapy
Family medicine
Immunotherapy
Pathology
Bevacizumab
Epidermal growth factor receptor
Adenocarcinoma